Skip to NavigationSkip to content

heart failure

AZ's Farxiga becomes first FDA-approved SGLT2 inhibitor for heart failure with reduced ejection fraction

The FDA has moved to approve an oral tablet formulation of AstraZeneca’s Farxiga (dapagliflozin) to reduce the risk of cardiovascular death and hospitalisation in adult patients with New York Heart Association’s functional class II-IV heart failure with reduced ejection fraction.

The decision makes the drug the first  sodium-glucose co-transporter 2 (SGLT2) inhibitor available in the US in this indication.

Type 2 diabetes drug Rosiglitazone increases risk of heart problems

A new study has given further evidence that rosiglitazone can contribute to risk of heart problems and heart failure.

The British Medical Journal study was led by the Yale School of Public Health. It analysed the results of more than 130 trials involving over 48,000 adult patients that compared rosiglitazone with any control for at least 24 weeks. Individual Patient Data (IPD) was available for 33 trials, included 21156 patients. The remaining trials only had summary level data available.

Novartis' Entresto narrowly misses Phase 3 goal in heart failure patients

New Phase 3 data for Novartis’ Entresto (sacubitril/valsartan) have been released, showing that the therapy narrowly missed its primary endpoint but still presented clinical benefit compared to valsartan in heart failure patients with preserved ejection fraction (HFpEF).

The findings of the study showed that Entresto reduced the total (first and recurrent) heart failure hospitalisations and cardiovascular (CV) death experienced by patients by 13%, falling just short of the primary endpoint.

Novartis' Entresto falls short at Phase 3 in heart failure with preserved ejection fraction

Novartis has been rocked by new Phase 3 data from a global trial into the efficacy of Entresto (sacubitril/valsartan), revealing that the therapy failed to meet its composite primary endpoint in the treatment of patients who have suffered heart failure with preserved ejection fraction (HFpEF).

The company confirmed that the therapy “narrowly missed statistical significance” in the reduction of cardiovascular death and total heart failure hospitalisations compared to active comparator valsartan in 4,822 participants – the largest study into HFpEF to date.  

Novartis' Entresto tops enalapril in stabilised heart failure patients

Novartis has declared new findings for Entresto (sacubitril/valsartan) at the American Heart Association's (AHA) scientific sessions, showing that the drug proved itself superior to enalapril-a in patients with heart failure with reduced ejection fraction (HFrEF) who had been stabilised following hospitalisation for an acute decompensation heart failure (ADHF) event.

AstraZeneca jettisons European heart drug rights for $210m

AstraZeneca has announced its intention to hand over the European commercial rights to its heart failure and blood pressure treatment Atacand (candesartan) to German pharmaceutical firm Cheplapharm Arzneimittel for $210 million.

Bayer expands Broad Institute partnership to focus on heart failure

The Broad Institute of MIT and Harvard has expanded its partnership with Bayer through the launch of the Precision Cardiology Laboratory (PCL), which will focus on developing new therapeutics for heart failure.

The PCL will be situated at the Massachusetts-based biomedical and genomic research centre. The cardiology lab will leverage new tools and approaches in an effort to gain greater insight into the causes of heart failure while working towards developing methods to treat associated conditions.

Novartis' Entresto helps preserve kidney function in chronic heart failure patients

Novartis has lifted the curtain on new data from a Phase 3 trial investigating the efficacy of Entresto (sacubitril/valsartan) in preserving kidney function in patients with heart failure with reduced ejection fraction (HFrEF), demonstrating that those taking the drug experienced a slower rate of decline in estimated glomerular filtration rate (eGFR).

Teva spared payout to GSK over patent infringement dispute

Teva has been spared a sizeable payout to GlaxoSmithKline after a federal judge overturned a US jury verdict demanding that the Israeli firm hand over $235 million in damages related to infringement of one of the latter’s patents.

Battling misinformation on the world’s biggest killer

Published on 14/08/17 at 12:37pm

Simon Williams, Head of Communications and Policy at Heart UK, discusses the threat posed by cholesterol in the development of cardiovascular conditions, and how statins are key to solving the problem, if the treatment could only escape unwarranted criticism.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches